Bone News and Research

RSS

Exactech receives FDA marketing clearance for Equinoxe Platform Fracture Stem

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the company’s Equinoxe® Platform Fracture Stem, the latest addition to the company’s shoulder arthroplasty line.

3 Mar 2010

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.

3 Mar 2010

Bisphosphonate drugs used to prevent osteoporosis may also help reduce risk of breast cancer

A DRUG commonly used to prevent and treat bones losing density and becoming brittle - known as osteoporosis - may also help reduce the risk of breast cancer by one third or more according to new research published in the British Journal of Cancer today (Wednesday).

3 Mar 2010

Study shows cryoablation technique offers a potential treatment for breast cancer

Freezing a cancer kills it in its place, and also appears to generate an immune response that helps stop the cancer's spread, leading to improved survival rates over surgery, according to a new study in mice from researchers at the University of Michigan Comprehensive Cancer Center.

3 Mar 2010

Corgenix Medical announces the availability of new automation friendly anti-phospholipid assay format

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has announced the availability of its new automation friendly anti-phospholipid assay format.

2 Mar 2010

Pre-clinical study of Cardio3 BioSciences' proprietary C-Cath catheter announced

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.

2 Mar 2010

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

A newly identified cancer biomarker could define a new subtype of breast cancer as well as offer a potential way to treat it, say researchers at Washington University School of Medicine in St. Louis. Their findings will be published in the March 1 online early edition issue of the Proceedings of the National Academy of Sciences.

2 Mar 2010

Researchers develop sensitive measuring system for cGVHD

Researchers from The University of Texas M. D. Anderson Cancer Center have developed a new assessment tool to measure the severity of symptoms that can complicate stem cell transplantation. The tool assesses symptoms resulting from chronic graft-versus-host disease (cGVHD), and was presented with supporting research at the 2010 Bone and Marrow Transplant Tandem Meeting.

2 Mar 2010

Stryker Interventional Spine announces the U.S. launch of VertaPlex HV bone cement for VCFs

Stryker Interventional Spine today announced the U.S. launch of VertaPlex® HV. VertaPlex HV is a high viscosity bone cement for use in treating vertebral compression fractures.

From Stryker 2 Mar 2010

Baxter International to acquire outstanding equity of ApaTech for $330 million

Baxter International Inc., a global, diversified healthcare company, and ApaTech, a private equity-backed, U.K.-based orthobiologic products company, today announced a definitive agreement whereby Baxter will acquire all of the outstanding equity of ApaTech for total consideration of up to $330 million.

From Baxter International Inc. 2 Mar 2010

Study shows high rate of shoulder dislocation in young males and elderly women

An article published in the March 2010 issue of The Journal of Bone and Joint Surgery reveals that the majority of all shoulder dislocations occur during sports activities and young males are at a higher risk. The study also shows a high rate of shoulder dislocation in elderly women.

2 Mar 2010

$Visceral fat can increase fracture risk in obese teenage girls$

Visceral fat can increase fracture risk in obese teenage girls

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), obese teenage girls with a greater ratio of visceral fat (fat around internal organs) to subcutaneous fat (fat found just beneath the skin) are likely to have lower bone density than peers with a lower ratio of visceral to subcutaneous fat.

2 Mar 2010

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

ARIAD Pharmaceuticals, Inc. today announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S., the orphan designation of AP24534 is for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and in the E.U., its orphan designation is for CML and acute lymphoblastic leukemia.

2 Mar 2010

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation.

1 Mar 2010

Precise immune disturbances leading to Coeliac disease: More insight

New research has identified four aspects of immune system disturbance which lead to the development of coeliac disease. Nearly 40 different inherited risk factors which predispose to the disease have now been identified. These latest findings could speed the way towards improved diagnostics and treatments for the autoimmune complaint that affects 1 in 100 of the population, and lead to insights into related conditions such as type 1 diabetes.

28 Feb 2010

Unexplained, sudden anemia: Brown recluse spider bite

As spring approaches and people return to outdoor activities, caution should be taken in areas of the country that are home to Loxosceles reclusa, also called the brown recluse spider. A new study from St. Jude Children's Research Hospital found that when patients present with sudden anemia, but the cause is elusive, the brown recluse spider should be part of the differential diagnosis, at least in parts of the nation where the spider is regularly found.

27 Feb 2010

Body repairs itself through microvesicles: New hope for tissue regeneration

Researchers at Rhode Island Hospital have discovered how cells communicate with each other during times of cellular injury. The findings shed new light on how the body repairs itself when organs become diseased, through small particles known as microvesicles, and offers hope for tissue regeneration.

27 Feb 2010

"Smart Hip": Non-evasive method to regenerate bone tissue

To monitor the real-time performance of bone implants is the challenge of "Smart Hip", an innovative medical device that aims to reduce the number of surgical interventions in the hip area and regenerate bone tissue by using non-evasive methods. The concept's validation - unique in the world and developed by a PHD from the Faculty of Engineering of the University of Porto -, has already been successfully tested on animals.

27 Feb 2010

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Marking a shift in decades of thought on the cause of osteoporosis, researchers at the University of Arkansas for Medical Sciences have identified an age-related mechanism - not a decrease of the hormone estrogen - as the primary culprit.

27 Feb 2010

Shire receives marketing approval from FDA for VPRIV

Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.

27 Feb 2010

Bone News and Research

Exactech receives FDA marketing clearance for Equinoxe Platform Fracture Stem

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Bisphosphonate drugs used to prevent osteoporosis may also help reduce risk of breast cancer

Study shows cryoablation technique offers a potential treatment for breast cancer

Corgenix Medical announces the availability of new automation friendly anti-phospholipid assay format

Pre-clinical study of Cardio3 BioSciences' proprietary C-Cath catheter announced

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

Researchers develop sensitive measuring system for cGVHD

Stryker Interventional Spine announces the U.S. launch of VertaPlex HV bone cement for VCFs

Baxter International to acquire outstanding equity of ApaTech for $330 million

Study shows high rate of shoulder dislocation in young males and elderly women

Visceral fat can increase fracture risk in obese teenage girls

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Precise immune disturbances leading to Coeliac disease: More insight

Unexplained, sudden anemia: Brown recluse spider bite

Body repairs itself through microvesicles: New hope for tissue regeneration

"Smart Hip": Non-evasive method to regenerate bone tissue

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Shire receives marketing approval from FDA for VPRIV

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News